The new funding from Business Finland comes on the heels of a successful financing round announced last week.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
Amplidiag CarbaR+MCR detects the main carbapenemase-producing organisms and colistin resistance markers. Novidiag Bacterial GE+ identifies the most common enteric pathogens.
The deal covers all Amplidiag tests and the Amplidiag Easyinstrument, and represents Mobidiag's entry into the Baltic region, a company executive said.
The test, designed to simultaneously detect diarrhea-causing enteric viruses using DNA extracted from a stool sample, includes norovirus GI, norovirus GII, and others.
PerkinElmer's subsidiary Wallac will now distribute the Amplidiag product line in Israel and in a number of countries in Africa.
The funding was supported by Finnish investment service company Kansalaisrahoitus Oy.
The deal covers Mobidiag's full line of Amplidiag tests for gastrointestinal infections, as well as the high-throughput Amplidiag Easy system.
The firm received the CE IVD mark for Amplidiag Easy, an automated system that enables nucleic acid extraction and PCR setup directly from stool samples.
US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.
Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.
In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.
In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.